ClinicalTrials.gg
CompletedNCT05383898Updated Oct 15, 2024

Study to Evaluate D-1553 in Subjects With Lung Cancer

A Phase 1/2 interventional study of D-1553 in NSCLC, sponsored by InventisBio Co., Ltd. Completed at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by InventisBio Co., Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2023, 3 years ago, and no results have been posted to the registry.
  • Registered 1 year 1 month after the study started (first participant enrolled Mar 2021, registered May 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
225
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase 1/2, open label study of D-1553 single agent treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic NSCLC with KRasG12C mutation

02

Conditions studied

  • NSCLC
03

In context

Lead sponsor

InventisBio Co., Ltd is the lead sponsor of 34 studies on the registry; 11 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject with proven, locally advanced, unresectable and/or NSCLC for which no standard treatment is available or the subject is to or intolerant of existing standard treatment.
  • Subject has KRasG12C mutation in tumor tissue or other biospecimens containing cancer cells or DNA. Historical, local laboratory result (up to 5 years prior to this study) can be used for Phase 1 subjects. Phase 2 subjects must be tested for KRasG12C mutation by a central laboratory.
  • Subject has according to , v1.1

Exclusion criteria

Exclusion Criteria:

  • Subject with unstable or progressive central nervous system (CNS) .
  • Subjects with cardiovascular disease
  • Subject with interstitial lung disease (ILD) or any active systemic infection including but not limited to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
  • Subject has impaired gastrointestinal (GI) function or GI diseases that may significantly alter the absorption or metabolism of oral medications.
  • Subject is pregnant or lactating.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    Phase 1a Dose escalation of D-1553

    Phase 1a will evaluate up to sequential cohorts with different doses of D-1553 to determine safety, tolerability, MTD and RDE in patients with solid tumors with KRasG12C mutation

    Drug: D-1553

  • Experimental
    Phase 1b Dose expansion of D-1553

    Phase 1b will evaluate more subjects with up to 2 different doses of D-1553 to confirm the recommended phase 2 dose.

    Drug: D-1553

  • Experimental
    Phase 2 of D-1553 monotherapy

    Phase 1b will evaluate more subjects at the recommended phase 2 dose of D-1553 to evaluate the efficacy.

    Drug: D-1553

Interventions

  • DrugD-1553

    D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.

06

What researchers measure

Primary outcomes

  1. Subject incidence of Dose-limiting toxicities (DLT)

    Subject incidence of Dose-limiting toxicities (DLT)

    Time frame: through out the DLT period, approximately 21 days

  2. Number of subjects participants with adverse events

    Number of subjects participants with adverse events

    Time frame: Through study completion, approximately 3 years

  3. antitumor activity of D-1553 in subjects with advanced or metastatic NSCLC with KRASG12C mutation

    Overall Response Rate (ORR, Complete Response \[CR\] + Partial Response \[PR\])

    Time frame: Through study completion, approximately 3 years

Secondary outcomes

  1. Plasma concentration of D-1553

    Plasma concentration of D-1553 as a single agent in subjects with advanced or metastatic NSCLC with KRas G12C mutation

    Time frame: approximately 6 months

07

Study locations

2 sites
  • Shanghai Chest Hospital
    Shanghai, Shanghai 200030, China
  • Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences,
    Hangzhou, Zhejiang 310005, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Nov 2023, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2022
First posted
May 20, 2022
StartActual
Mar 16, 2021
Primary completionActual
Nov 17, 2023
CompletionActual
May 17, 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05383898
Responsible party
Sponsor
First posted
May 20, 2022
Start date
Mar 16, 2021
Primary completion
Nov 17, 2023
Completion
May 17, 2024
Last update
Oct 15, 2024

Study contacts

Shun Lu, MD
principal investigator · Shanghai Chest Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garsorasib

Start the discussion